Calorie-restricted oat diet is associated with zonulin and short-chain fatty acid response in metabolic syndrome: a randomized controlled trial.

Gut MicrobesApr 23, 2026 (epub)
Clinical ResearchGastroenterologyEndocrinologyOpen access

Linda Klümpen, Aakash Mantri, Anna Donkers et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the effects of two oat diets on gut permeability markers in individuals with metabolic syndrome. Participants consuming a calorie-restricted oat diet showed a decrease in serum zonulin and an increase in plasma butyric acid compared to baseline. The study involved 27 participants for the short-term diet and 22 for the long-term diet.

Key findings

  • Serum zonulin decreased upon a 2-day calorie-restricted oat diet compared to baseline.
  • Plasma butyric acid increased compared to the control diet.
  • Zonulin reduction correlated inversely with changes in short-chain fatty acids, particularly valeric and butyric acids.
  • Microbial composition shifts were associated with the dietary changes.

Why it matters

Understanding the impact of dietary interventions on gut permeability can inform strategies to manage metabolic syndrome. Improved gut health may contribute to better metabolic outcomes in affected individuals.

Source

Published in Gut Microbes. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.